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of urinary bladder dysfunction in mice. Thalidomide was applied either during the early or late response phase to determine
potential effects of NF-kB inhibition on functional bladder impairment.
Methods and Materials: After pelvic irradiation on day 0, female C3H/Neu mice were observed over a period of 360 days
and radiation response was evaluated for alterations in bladder functionality and NF-kB activation. Functionality was deter-
mined in graded dose experiments (14-24 Gy) and assessed by micturition frequency analysis and transurethral cystotono-
metry to reveal alterations in voiding and volume. The induction of the NF-kB proteins p50 and p65 was evaluated by
immunohistochemistry in response to a single dose of 23 Gy (ED90). Thalidomide (100 mg/kg/d) was applied intraperitone-
ally in 3 treatment groups: daily from day 1 to 15, daily from day 16 to 30, and in 2-day-intervals from day 150 to 180.
Results: Immunohistochemical analysis showed a biphasic activation of p50 and p65 during the early radiation cystitis phase
(day 1-30). After a transient decrease, p50, but not p65, was reactivated permanently leading to increased levels, which sug-
gests an occurrence of chronic inflammation correlated with functional impairment. Both early thalidomide treatments
reduced NF-kB activation and shifted the ED50 value for early radiation cystitis and late radiation sequelae to higher doses.
Conclusions: These data clearly demonstrate the involvement of NF-kB signaling in the pathogenesis of radiation-induced
urinary bladder dysfunction. Additionally, this study emphasizes that biological targeting of early radiogenic processes has
enormous effect on chronic symptoms. The late administration of thalidomide showed no significant effect on functionality.
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24,25During the course of pelvic radiation therapy, the urinary
bladder is exposed to particular doses that bear a certain,
but accepted, risk of adverse effects in favor of tumor
control.1 Radiogenic complications of the urinary bladder
are divided into early and late events. Early symptoms
mainly reported days to weeks after the onset of radiation
therapy are reversible and undergo conservative treat-
ments.2 However, a progressive and irreversible late phase
is preceded by a symptom-free period that persists for years
or even decades.3,4 The urologic symptoms comprise a
tremendous reduction of the bladder volume, leading to an
increased micturition frequency and nocturia, and include
dysuria, hematuria, and incontinence. In consideration of
continuously increasing curing rates, it is important to
manage chronic symptoms to further improve the patient’s
quality of life.
So far, no adequate treatment strategies exist to prevent,
reduce, or cure late radiation sequelae (LRS). The current
management of early radiation cystitis (ERC) indicates no
ameliorating effect on late complications, although insights
into the radiopathogenesis reveal a fundamental relation-
ship between early and late radiation responses, known as
consequential (late) effects.2,3,5 A biology-based interven-
tion that targets early radiation-induced mechanisms offers
a sophisticated approach to mitigate early radiation
sequelae and presumably LRS.
Radiation-induced reactions in the urothelium provoke
excessive inflammation that, in combination with an
impairment of the barrier function, triggers early symp-
toms.6,7 Preclinical studies demonstrated a biphasic upre-
gulation of COX-2,7 postulated as (1) a direct consequence
of ionizing irradiation8 and (2) a result of barrier impair-
ment.9 The mediated synthesis of prostaglandins increases
the tonus of the detrusor muscle, which reduces the bladder
volume, leading to increased micturition frequency and
accessory symptoms.10 An incomplete compensation of
radiation-induced urothelial cell depletion presumably
fosters persistent leakage of noxious urine that drives the
production of reactive oxygen species, inducing additional
trauma and consequential (late) effects.
Nuclear factor kB (NF-kB) is a pivotal transcription
factor that regulates immune cell activation and is associ-
ated with inflammatory processes.11-13 Hence, NF-kB is
also suspected to contribute to the development and pro-
gression of inflammation-promoted tumors, such as pros-
tate cancer.14,15 Ionizing radiation activates the NF-kB
signaling cascade directly or via the induction of double-
strand breaks and oxidative stress.16,17 Activated NF-kB
proteins form homo- and heterodimers to translocate to the
nucleus and enable the transcription of versatile
genes.11,12,18-20 The 2 NF-kB proteins p50 and p65 pref-
erentially form heterodimers that induce inflammatory gene
activation.21-23 Thalidomide interferes with the activation
of NF-kB, rationalizing its utilization for various clinicalmalignancies.
Based on the immunomodulatory effect of thalidomide,
this study aims to investigate the role of NF-kB and the
functional effect of thalidomide on radiogenic bladder
dysfunction. Therefore, the activation of p50 and p65 was
evaluated in single-dose experiments for 360 days and
correlated with functional assessments in female C3H/Neu
wild-type mice.Methods and Materials
Animals and housing
All animal experiments were performed in accordance with
the current laboratory animal welfare legislation with
approval of the respective authorities (Federal Ministry of
Education, Science and Research, file number BMWF-
66.009/0148-WF/II/3b/2014).
Groups of 5 C3H/Neu mice per cage (Tecniplast IVC
cages, Buguggiate, Italy) were kept on aspen wood
bedding (ABEDD, Lab & Vet Service GmbH, Köflach,
Austria) at 12/12-hour light/dark rhythm under specific
pathogen-free conditions. The temperature was set to 22C
to 24C at 45% to 65% humidity. Animals received stan-
dard mouse diet (Sniff Spezialdiäten GmbH, Soest, Ger-
many) and sterile filtered water ad libitum. For functional
studies (240 mice), each treatment group consisted of 60
animals split into 5 irradiation dose groups (12 animals per
group). Eight hundred eighty-five animals were designated
for immunohistochemistry (IHC) and divided into the
following treatment groups: nonirradiated control group
(216), irradiation control (216), thalidomide day 1 to 15
(216), thalidomide day 16 to 30 (141), and thalidomide
day 150 to 180 (96). In total, 1125 animals were examined
in this study.Irradiation
Small animal pelvic irradiation was described in previous
papers.26 Briefly, groups of 5 to 6 anaesthetized mice (60
mg/kg pentobarbitone sodium, intraperitoneally) at the
age of 10 to 12 weeks underwent single-dose irradiations
with a YXLON MG325 x-ray device (YXLON Interna-
tional GmbH, Hamburg, Germany) operating at 200 kV
and 20 mA. Animals were immobilized in a supine po-
sition, and the urinary bladders were positioned to a
corresponding 0.9 cm2 irradiation field. The bowel was
gently moved out of the irradiation field, and the rest of
the animal was shielded by a lead equivalent collimation
with the following composition: 3 mm Be, 4 mm Al, and
0.6 mm Cu. The dose rate was approximately 1 Gy/min
at the focus-to-surface distance of 45.5 cm. Dose ho-
mogeneity between the individual bladder positions
deviated by 3%.
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Animals were irradiated on day 0. Thalidomide was sys-
temically applied (100 mg/kg/d)22 in 3 treatment groups
daily from day 1 to 15, from day 16 to 30, or in 2-day
intervals from day 150 to 180. For functional studies,
groups of 12 mice received 14, 17, 19, 21, or 24 Gy single
irradiation and 23 Gy (ED90, dose at which 90% show
functional response based on the volumetric endpoint) for
immunohistochemical examinations. Transurethral cys-
totonometry (TC) was conducted every 3 days during the
early phase (day 3-30) and every 30 days during the late
(day 60-360) phase. Baseline values were measured within
2 weeks before irradiation. Micturition frequency analysis
was conducted in the late phase in 30-day intervals after
volumetric measurements assessed by TC. For each group,
5 urinary bladders were sampled daily from day 1 to 30 and
6 samples every 30 days from day 60 to 360 to detect p50
and p65 activation by IHC.Immunohistochemical analysis
Excised urinary bladders were fixed in 4% para-
formaldehyde (Roti-Histofix 4 % acid-free, pH 7, Roth) by
insertion of a transurethral catheter and incubated FOR 48
hours at room temperature. Sagittal halves were embedded
in paraffin, and tissue sections of 4 mm were rehydrated and
subjected to standard IHC procedure. Antigen retrieval was
performed by boiling the slides in citrate buffer, pH 6, at
100C for 10 minutes. Staining was performed with Vec-
tastain ABC rabbit kit (Vector Laboratories, Burlingame,
CA). Primary antibodies, purchased from Abcam (Cam-
bridge, MA) were incubated at 4C overnight and diluted
with Tris-buffered saline to the following concentrations:
p50 (ab7971, rabbit monoclonal) to 1:500 and p65 (ab7970,
rabbit monoclonal) to 1:500. 3,3-Diaminobenzidine chro-
mogen (Vector Laboratories) was used for signal precipi-
tation, and nuclei were counterstained with hematoxylin.
Antigen localization and intensity were determined with
an Olympus light microscope at 400 magnification.
Urothelial cells were counted in 5 sample-representing
fields using an optical grid (250 mm per field). NF-kB
activation was defined by the fraction of marker-positive
nuclei (brown) and the corresponding staining intensity.Transurethral cystotonometry
To determine the intravesical volume, a saline-filled tran-
surethral catheter (0.7 mm diameter IVC cannula, BD
NeoflonTM, Helsingborg, Sweden) was inserted into the
emptied bladder. The catheter was linked to an infusion
pump and to a pressure transducer by pressure-resistant
tubes. The saline instillation rate was set to 0.1 mL/min, the
transduced signal was detected, and a chart recorder used to
determine the intravesical volume at 10 mm Hg.Micturition frequency analysis
Groups of 5 mice were analyzed simultaneously. Each
mouse was set into a single cell with a permeable grid floor
allowing the collection of murine excretions on an absor-
bent paper that moved approximately 15 cm/h for 24 hours.
Food and water was provided ad libitum. Micturition spots
were detected on an ultraviolet plate, and pictures were
processed by ImageJ software to determine the micturition
frequency.
Statistical analysis and endpoints
Statistical analysis was performed by using SPSS software
version 24 and GraphPad Prism 7.00. For IHC, 5 or 6 an-
imals were analyzed per sampling day to obtain a mean and
standard deviation of positively stained nuclei for each
animal. Statistical significance between the treatment
groups and sampling days was calculated by 2-way analysis
of variance and Tukey post hoc testing. Functional analysis
based on the volumetric endpoint (>50% reduction of
intravesicular bladder volume at 10 mm Hg) was deter-
mined by TC. Dose-response curves were calculated by
probit analysis of 5 dose groups with 12 mice each. A
logarithmic function without a threshold dose was assumed.
Treatment effects were evaluated by ED50 values (esti-
mated dose at which 50% of animals show radiation
response as defined by the volumetric endpoint), and their
standard deviation applying likelihood-ratio analysis was
based on the logit model. For Kaplan-Meier curves, volu-
metric endpoint and micturition frequency endpoints (>1
micturition event per hour) were used to generate
complication-free survival curves. Log-rank test statistics
and the hazard ratio were calculated in GraphPad Prism to
determine treatment effects. A P value of <.05 was
regarded as statistically significant.
Results
Early radiation-induced activation of NF-kB
IHC demonstrated that the high single dose of 23 Gy
induced a biphasic activation of NF-kB proteins p50 and
p65 (Fig. 1) in ERC (day 1-30). The time courses of p50
and p65 (Fig. 1a, black) show 2 activation peaks but differ
in the residual amplitude of activation. p50 is activated in 2
well-defined peaks around day 6 and 21, separated by an
inactive phase showing p50 levels similar to not irradiated
control values. Compared with p50, p65 shows 2 expanded
and flattened peaks that are intermediately decreased
around day 12.
NF-kB appears to be activated in 2 phases, from day 1 to
15 (phase 1) and 16 to 30 (phase 2). Systemic administra-
tion of thalidomide in both early phases efficiently inhibited
the activation of both NF-kB proteins (Fig. 1a). Phase 1
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Fig. 1. Involvement of nuclear factor-kappa B (NF-kB) in the pathogenesis of early radiation cystitis (ERC), day 1 to 30.
(a) p50 and p65 activation course in response to single irradiation (23 Gy). Each data point (n Z maximum of 15 animals)
reflects an average of 3 successive time points (daily sampling, n Z maximum of 5 animals). The nonirradiated control
represents the mean activation and corresponding standard error of mean (SEM) of all samples from day 1 to 30 (n Z 50
animals). For 2-way analysis of variance (ANOVA), the irradiation control was compared with the following treatment
groups: nonirradiated control (black stars), thalidomide day 1 to 15 (blue stars), and thalidomide day 16 to 30 (green stars).
(b) Immunohistochemistry (IHC) illustrates marker localization in the urothelium including the representative staining of p50
and p65 on day 4 and 21 after irradiation alone or in combination with thalidomide application. For analysis, the fraction of
positive cells/nuclei (black arrows) was determined. Red arrows indicate no marker staining. )P < .05, ))P < .01, ))) P <
.001; scale bar Z 50 mm. (A color version of this figure is available at https://doi.org/10.1016/j.ijrobp.2020.01.028.)
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that NF-kB is slightly activated after thalidomide admin-
istration. Phase 2 application interfered with activation of
NF-kB after day 16 and showed a mitigating effect several
days after the onset of treatment. Histologic analysis(Fig. 1b) illustrates that thalidomide in both phases reduced
the frequency of positively stained nuclei.
The correlation of functional impairment (Fig. 2a) with
the time courses of NF-kB activation suggests that the in-
duction of p50 and p65 precedes the radiogenic reduction
Volume 107  Number 2  2020 Effect of thalidomide on radiation cystitis 381of urinary bladder volume. Both administrations resulted in
a drastic decrease in responding animals. In particular,
phase 1 treatment from day 1 to 15 reduced the incidence of
responding animals to approximately 25% of the irradiated
control.Late radiation-induced activation of NF-kB
In contrast to ERC (day 1-30), the activation time course
and intensity of p50 were different from p65 in the chronic
response phase (day 60-360). The activation of p65
(Fig. 3a) was maintained at slightly increased levels,
whereas the relative fraction of active p50 continuously
increased from its minimum on day 60 to reach a plateau
starting on day 150. Phase 1 and 2 applications of thalid-
omide attenuated the activation of p50 and postponed the
active plateau phase from day 150 to day 270. p65 is not
affected by thalidomide, indicating that it is not involved in
the late radiopathogenesis.
Thalidomide was applied from day 150 to 180 (phase 3)
to investigate effects on the late activation course and
amplitude of p50 and p65. Concomitant with previous re-
















































Fig. 2. Functional modifications of daily thalidomide admini
course of radiation-induced functional impairment is defined by a
(volumetric endpoint) assessed by transurethral cystotonometry
sponders in merged dose groups is illustrated. (c, d) Dose-respon
radiation response, based on the volumetric endpoint, with the ap
determined by comparison of corresponding 50% effective dos
likelihood ratio analysis based on the logit model. Radiation re
tervals between day 3 and 30. )))P < .001, n Z 60 animals.reduced during the administration period (Fig. 3b). This
effect is not persistent; p50 becomes rapidly reactivated
afterward and demonstrates a time course similar to that in
the irradiated control group. Histologic data show the
enduring inhibition effect of early thalidomide adminis-
tration on day 150 (Fig. 3c).
Functional consequences of thalidomide
application on early and late radiogenic sequelae
The therapeutic effect of thalidomide on ERC and LRS was
evaluated by dose-effect relationships based on volumetric
measurements. Phase 1 and 2 application of thalidomide
lowered the levels of active NF-kB (Fig. 1) and decreased
the fraction of early responding animals (Fig. 2a). Dose-
response analysis (Table 1, Fig. 2b) revealed that phase 1
treatment significantly increased radiation tolerance by
doubling the ED50 for early responses from 11.6  6.8 Gy
to 24.3  2.9 Gy. Phase 2 treatment also affected the ED50,
but it was not as pronounced as it was with phase 1
application.
Nevertheless, both early treatments significantly modi-
fied the development of the LRS (Fig. 4). The ED50 of then.s.
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Fig. 3. Role of nuclear factor-kappa B (NF-kB) in chronic radiation sequelae of the urinary bladder, day 60 to 360. (a, b)
p50 and p65 activation course in response to single irradiation (23 Gy). One data point (nZ maximum of 12 animals) reflects
an average of 2 successive time points (30-day intervals, n Z maximum of 6 animals). The nonirradiated control represents
the mean activation and corresponding standard error of mean (SEM) of all samples from day 30 to 360 (n Z 60 animals).
For 2-way analysis of variance (ANOVA) analysis, the irradiation control was compared with the following treatment groups:
nonirradiated control (black stars), thalidomide day 1 to 15 (blue stars), thalidomide day 16 to 30 (green stars), and
thalidomide day 150 to 180 (yellow stars) treatment group. (c) Immunohistochemistry (IHC) illustrates marker localization in
the urothelium including the representative staining on day 150. The inhibitory effect of late thalidomide administration is
shown on day 178. For analysis, the fraction of positive cells/nuclei (black arrows) was determined. Red arrows indicate no
marker staining. )P < .05, ))P < .01, )))P < .001; scale bar Z 50 mm. (A color version of this figure is available at
https://doi.org/10.1016/j.ijrobp.2020.01.028.)
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SD, Gy P dose P value
Early phase
(day 1-30)
Irradiation control 11.6  6.8 .009 -
Thalidomide 1-15 24.3  2.9 .0014 .001
Thalidomide 16-30 14.9  4.8 <.001 .388
Late phase
(day 60-360)
Irradiation control 10.4  3.9 <.001 -
Thalidomide 1-15 19.6  2.5 <.001 <.001
Thalidomide 16-30 17.1  2.8 <.001 .01
Thalidomide 150-180 14.2  3.0 <.001 .158
Abbreviations: ED Z effective dose; SD Z standard deviation.
nZ 60 animals, 5 dose groups (14-24 Gy). P dose refers to the dose-
effect relationship, and P value determines the treatment effect.
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19.6  2.5 Gy and 17.1  2.8 Gy in response to phase 1
and 2 thalidomide treatment, respectively. Late adminis-
tration of thalidomide resulted in minor changes in the
ED50. The inefficiency of late treatment was already sug-
gested by mechanistic studies demonstrating that thalido-
mide has no long-lasting effects on chronic NF-kB (p50)
activation.
The ameliorating effect of early thalidomide adminis-
tration was also demonstrated by the complication-free
survival analysis using Kaplan-Meier curves (Fig. 4a, 4b,
Table 2). Regarding the volumetric endpoint (Fig. 4a),
thalidomide postponed the median incidence of the late
response from day 150 to day 300 (phase 1 and 2 treat-
ment). Phase 3 administration showed no relevant modi-
fications. The micturition frequency analysis endpoint
(Fig. 4b), revealed to be less sensitive as functional
response, was drastically decreased compared with the
volumetric endpoint. We assume that the generally
reduced functional response potential hid treatment
effects.
Discussion
Histologic analyses of irradiated urinary bladders
demonstrated a biphasic radiation-induced activation of
p50 and p65 in ERC (day 1-30). The formation of a p50/
p65 heterodimer emphasizes that early symptoms are
based on inflammatory processes.18,21,23 p50/p65 is acti-
vated by the canonical pathway, leading to the upregula-
tion of inflammatory genes. The biphasic time course
correlates with previously demonstrated COX-2 activationthat is regulated by NF-kB and drives the prostaglandin
synthesis, contributing to early adverse effects. The rela-
tionship between the time course of NF-kB activation and
functional impairment reveals that functional responses
manifest with a certain delay after the onset of inflam-
matory processes, suggesting the involvement of further
pathways.
During the chronic phase, only p50 was revealed to be
constantly activated, reaching an expression plateau on
day 150. p50 homodimers are associated with the
expression of nitric oxide synthase 2,27 interleukin-6,28
and interleukin-10,29 which are the driving factors for
chronic inflammation.14,27 Thus, we assume that LRS is
based on urothelial inflammation, presumably triggered
by an incomplete compensation of radiation-induced
urothelial cell depletion and a successive impairment of
the barrier function. The interplay of a leaky urothelium
and chronic inflammation emphasizes the importance of
consequential late side effects because these factors are
directly modified by the severity of early reactions. This
explains the patient-to-patient variation in latency of the
symptom-free phase, which is inversely dose dependent.
An intense early phasedinfluenced by inflamma-
tiondincreases the risk and degree of incomplete barrier
repair, which favors the development of late effects and
reduces the latent period.
Our data demonstrated that early thalidomide admin-
istration effectively attenuated p50 and p65 activation in
both the early and late phase. This effect was confirmed
in functional studies in which both early thalidomide
treatments significantly increased the ED50 value for
LRS. Furthermore, our data show that phase 1 treatment
resulted in the most beneficial radioprotective effects.
Considering thalidomide as a therapeutic agent to
manage urinary bladder impairment, our data suggest
that applications during the early symptomatic phase
have beneficial and promising effects on the incidence
and severity.
Current therapy approaches comprise bladder irriga-
tions with a wide spectrum of diverse compounds. Alum
and formalin target severe hematuria, whereas the
instillation of glycosaminoglycans aims to protect the
urothelium from mechanical and chemical stress.2,3,30
Systemic therapy approaches, such as the administra-
tion of TCDO/WF10, take advantage of immunomodu-
latory properties.31,32 Most systemic and local
treatments that showed therapeutic modifications did not
affect the development of chronic radiation fibrosis.
Hyperbaric oxygen treatment is proposed to reduce tis-
sue fibrosis; several clinical studies have revealed
beneficial results, but long-term follow-up elucidated the
recurrence of fibrosis and poor clinical response of pa-
tients.33,34 All in all, there is still a lack of appropriate
treatments, suggesting thalidomide should be tested in
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Fig. 4. Functional modifications of thalidomide administration on chronic radiation sequelae. Kaplan-Meier analysis of
complication-free survival referred to 2 functional response endpoints: (a) the volumetric endpoint, defined by an individual
>50% reduction of bladder compliance (volumetric endpoint), and (b) micturition frequency analysis (MFA), defining a
functional response by a micturition frequency of >1 event/hour (micturition frequency endpoint). All dose groups were
merged (n Z 60 animals). (c, d) Dose-response curves were generated by probit analysis correlating with radiation response,
based on the volumetric endpoint, with the applied dose (14, 17, 19, 21, or 24 Gy). Treatment effects were determined by
comparison of corresponding 50% effective dose (ED50) values ( standard deviation [SD]), applying the likelihood ratio
analysis based on the logit model. Radiation response (volumetric endpoint) was determined in 30-day intervals between day
60 and 360. )))P < .001, n Z 60 animals.
Table 2 Kaplan-Meier complication-free survival
Mean
complication-free
survival  SEM, d




(Mantel-Haenszel) 95% CI of ratio
Volumetric endpoint (>50% reduction of bladder volume)
Irradiation control 166  13 - - -
Thalidomide day 1-15 275  13 <.0001 0.2877 0.173-0.4787
Thalidomide day 16-30 262  13 <.0001 0.343 0.208-0.5664
Thalidomide day 150-180 198  14 .1168 0.6939 0.4395-1.096
Micturition frequency endpoint (>1 event/hr)
Irradiation control 216  4 - - -
Thalidomide day 1-15 243  4 .0001 0.5133 0.3649-0.722
Thalidomide day 16-30 260  3 <.0001 0.2656 0.186-0.3798
Thalidomide day 150-180 216  5 .9065 0.9837 0.7471-1.295
Abbreviations: CI Z confidence interval; MFA Z micturition frequency analysis; SEM Z standard error of the mean.
Analysis based on volumetric endpoint and MFA endpoint. Reciprocal hazard ratio describes treatment efficiency compared with the irradiation control.
Merged dose groups; n Z 60 animals.
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ERC and LRS are based on inflammatory processes in the
urothelium. Single irradiation doses activated the NF-kB
proteins p50 and p65 during early events, suggesting the
formation of heterodimers that induce proinflammatory
genes. Contrarily to the early phase, only p50 is activated in
chronic reactions, indicating the formation of p50 homo-
dimers that are associated with chronic inflammation.
Thalidomide inhibited p50 and p65 induction signifi-
cantly and affected the development and severity of early
and late adverse effects. Early treatments increased the
ED50 values for ERS and LRS, whereas the late adminis-
tration of thalidomide did not show any beneficiary effects.References
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